文献速递肝病

KLF9通过抑制NR4A1-p38 MAPK肝脏代谢轴驱动间歇性缺氧诱导的MASLD

KLF9 drives intermittent hypoxia-induced MASLD by suppressing the NR4A1-p38 MAPK hepatic metabolic axis.
PubMed 文献 · Hepatology · 2025-11-04

该研究通过小鼠和细胞间歇性缺氧(IH)模型,结合代谢与分子分析,发现IH上调肝脏KLF9,KLF9直接结合NR4A1启动子抑制其转录及下游p38 MAPK活化,从而促进肝脏脂肪生成和炎症;靶向KLF9-NR4A1轴可能为OSA相关MASLD提供新治疗策略。

要点

  • 间歇性缺氧上调肝脏KLF9,加重脂肪变性和胰岛素抵抗。
  • KLF9直接抑制NR4A1转录,减少p38 MAPK活化,促进脂肪生成。
  • 靶向KLF9-NR4A1轴可能治疗OSA相关MASLD。

核心结论

  • KLF9是驱动间歇性缺氧相关MASLD的关键转录调节因子,通过抑制NR4A1及p38 MAPK信号促进肝脏脂肪生成。

研究设计与样本

  • 建立小鼠和细胞间歇性缺氧模型,进行葡萄糖和胰岛素耐量试验、生化分析、组织学、脂质组学、实时定量PCR、蛋白质印迹、RNA测序、染色质免疫沉淀测序、ChIP assay、共免疫沉淀和荧光素酶报告基因检测。

主要发现

  • 间歇性缺氧暴露在正常和肥胖小鼠中均诱导肝脏脂质积累和胰岛素抵抗,并伴随脂质代谢通路的转录重编程。
  • 转录组分析确定KLF9在间歇性缺氧处理后显著上调。
  • 肝脏过表达KLF9加重、而敲低KLF9减轻间歇性缺氧诱导的脂肪变性、脂肪生成和炎症。
  • KLF9直接结合NR4A1启动子内保守的富GC基序,抑制NR4A1转录和下游p38 MAPK活化。
  • 药理学调节NR4A1证实其在介导间歇性缺氧下KLF9驱动的脂肪生成中的调节作用。

临床怎么用

  • 靶向KLF9-NR4A1轴可能为管理OSA及其他缺氧相关疾病患者的MASLD提供新治疗途径。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Obstructive sleep apnea (OSA), characterized by recurrent episodes of intermittent hypoxia (IH), is increasingly recognized as a contributor to metabolic disorders, including metabolic dysfunction-associated steatotic liver disease (MASLD). However, the causal relationship and underlying molecular mechanisms linking IH and MASLD remain incompletely understood, hindering the development of effective therapeutic strategies. APPROACH AND RESULTS: We established murine and cellular models of IH and performed comprehensive metabolic and molecular profiling, including glucose and insulin tolerance tests, biochemical analyses, histology, lipidomics, real-time quantitative PCR, western blotting, RNA sequencing, chromatin immunoprecipitation (ChIP) sequencing, ChIP assay, co-immunoprecipitation, and luciferase reporter gene assays, to investigate the impact of IH and the role of KLF9 in hepatic lipid metabolism. The findings showed IH exposure induced hepatic lipid accumulation and insulin resistance in both normal and obese mice, accompanied by transcriptional reprogramming of lipid metabolic pathways. Transcriptomic analysis identified KLF9 as significantly upregulated by IH treatment. Functional studies demonstrated that hepatic overexpression of KLF9 exacerbated, while its knockdown alleviated, IH-induced steatosis, lipogenesis, and inflammation. Mechanistically, KLF9 directly binds to a conserved GC-rich motif within the NR4A1 promoter, suppressing NR4A1 transcription and downstream p38 MAPK activation. Pharmacologic modulation of NR4A1 further confirmed its regulatory role in mediating KLF9-driven lipogenesis under IH. CONCLUSIONS: This study identifies KLF9 as a key transcriptional regulator driving IH-associated MASLD by repressing NR4A1 and inhibiting p38 MAPK signaling, thereby promoting hepatic lipogenesis. Targeting the KLF9-NR4A1 axis may offer a novel therapeutic approach for managing MASLD in patients with OSA and other hypoxia-related disorders.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Hua H, Wang D, He L, et al. KLF9 drives intermittent hypoxia-induced MASLD by suppressing the NR4A1-p38 MAPK hepatic metabolic axis. Hepatology. 2025. PMID: 41190983. doi:10.1097/HEP.0000000000001606

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。